Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Hormone Secretion in Transgender Males
NCT04321551 · University of California, San Diego · PHASE4 · withdrawn · last registry update 2025-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “study not funded in previous iteration. new clinicaltrials.gov protocol submitted for funded version of study” | – | Registry record, University of California, San Diego |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-23Results posted on the registry: VA Office of Research and Development, Testosterone gel 1.62% + Placebo (NCT03887936)
- 2025-09-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Gonadotropin Releasing Hormone Agonists and Antagonists + Bicalutamide (NCT06528210)
- 2025-08-05Also stopped (terminated): The University of Queensland, Danazol + Placebo (NCT04638517)
- 2025-07-31Phase 3 first posted: Jaeb Center for Health Research, Atropine + Placebo Eyedrops (NCT07095894)
- 2025-07-22Also stopped (terminated): University of California, San Diego, Testosterone Cypionate 50 MG/ML Injectable Solution (NCT06450405)
- 2025-07-22Also stopped (withdrawn): University of Nebraska, Bicalutamide (NCT06501911)
- 2025-07-14Results posted on the registry: University of California, San Diego, Testosterone Cypionate 50 MG/ML Injectable Solution (NCT06450405)
- 2025-03-24Results posted on the registry: Imperial College London, a drug against AR (NCT04049747)
- 2025-03-14Results posted on the registry: Endo USA Inc., a Keenova Therapeutics Company, Aveed Injectable Product + Fortesta (NCT04456296)
- 2025-03-07Phase 3 first posted: Singapore National Eye Centre, a drug against AR (NCT06863675)
- 2025-02-13Results posted on the registry: Kimberly Myer, Nestorone® /testosterone gel + Testosterone only gel (NCT02432261)
- 2024-12-13Results posted on the registry: Peter Kovacs MD, Follitropin Alfa + Follitropin delta (NCT05103228)
- 2024-11-14Phase 3 first posted: Halozyme Therapeutics, Testosterone enanthate (NCT06689085)
- 2024-10-21Phase 3 first posted: Emory University, Abiraterone Acetate + Bicalutamide (NCT06650579)
- 2024-10-16Results posted on the registry: RTOG Foundation, Inc., Enzalutamide + Bicalutamide (NCT03809000)
- 2024-08-26Results posted on the registry: Palo Alto Veterans Institute for Research, Testim, 1% testosterone gel (NCT00645658)
- 2024-08-09Also stopped (terminated): University Medical Center Groningen, AndroGel (NCT05156606)
- 2024-07-29Phase 3 first posted: Johns Hopkins University, Cysview (NCT06525571)
- 2024-07-23Also stopped (terminated): Icahn School of Medicine at Mount Sinai, Danazol (NCT00953771)
- 2024-07-17Results posted on the registry: Lipocine Inc., LPCN 1144 (NCT04685993)
- 2024-07-08Phase 3 first posted: University Medical Centre Ljubljana, Semaglutide + Testosterone Undecanoate (NCT06489457)
- 2024-06-28Results posted on the registry: Marius Pharmaceuticals, SOV2012-F1 (NCT04467697)
- 2024-05-23Also stopped (terminated): Carelon Research, Oxandrolone (NCT04090697)
- 2024-05-22Also stopped (terminated): Fundacion Dexeus, Testosterone gel + Placebo gel (NCT02418572)
- 2024-04-24Also stopped (withdrawn): Baylor College of Medicine, Natesto Nasal Product (NCT04717362)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision